AVXS AveXis, Inc.

72.84
+0  (0%)
Previous Close 72.66
Open 72.79
Price To book 8.18
Market Cap 2.02B
Shares 27,739,000
Volume 313,281
Short Ratio 16.68
Av. Daily Volume 419,810

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Initiate pivotal trial in 2Q 2017 pending a successful outcome of its FDA Type B CMC meeting.
AVXS-101
Spinal muscular atrophy (SMA) Type 1

Latest News

  1. AVEXIS, INC. Financials
  2. Cytokinetics SMA Drug Did Well in Early Study
  3. Billionaires' Best Healthcare Stock Picks of 2017 (So Far)
  4. AveXis, Inc. (AVXS) Looks Good: Stock Moves 15.4% Higher
  5. AveXis Inc Stock Is Spiking Again Today -- Here's Why
  6. (video)AveXis, Esperion and Amgen Among Biotech Movers
  7. AveXis Reports Positive Data for SMA Gene Therapy
  8. AveXis Offers Easily The Best Treatment Option For SMA Type-1 Patients
  9. PBM Capital Group has completed the sale of a majority interest in Breas Medical Group to Fosun Pharma
  10. Edited Transcript of AVXS earnings conference call or presentation 16-Mar-17 8:30pm GMT
  11. Futures Steady: 2 'A' Stocks Set To Soar, 1 Mule Ready To Kick
  12. AveXis reports 4Q loss
  13. AveXis reports 4Q loss
  14. AVEXIS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD Disclosure, Financial S
  15. AveXis Reports Topline Results from Phase 1 Trial of AVXS-101 in SMA Type 1 and Fourth Quarter and Full Year 2016 Financial and Operating Results
  16. Q4 2016 AveXis Inc Earnings Release - After Market Close
  17. 5 Earnings Short-Squeeze Plays: Tiffany, Athene and More
  18. Blog Coverage Heat Biologics Acquires Controlling Stake in Immuno-Oncology Company Pelican Therapeutics
  19. AveXis to Report Topline Phase 1 Trial Results in SMA Type 1 and Fourth Quarter and Full Year 2016 Financial and Operating Results on March 16, 2017
  20. Puma Leads Massive Biotech Surge As Esperion Hits 15-Month High